This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (26)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Ophthalmology, Other  • Alert me on articles by topic

Johan Stjernschantz, MD, PhD; Göran Selén, PhD; Maria Astin, PhD; Maritha Karlsson; Bahram Resul, PhD

Arch Ophthalmol. 1999;117:1363-1367.

Objective  To evaluate the effects of latanoprost on regional blood flow and capillary permeability in the monkey eye.

Methods  Anesthetized cynomolgus monkeys were unilaterally treated with a single dose containing 6 µg of latanoprost; or 10 µg of PhXA34 (13,14-dihydro-15R, S-17-phenyl-18,19,20-trinor-prostaglandin F₂ [PGF₂]-isopropyl ester), which contains about 50% latanoprost. Regional blood flow in the eye was measured with radioactively labeled microspheres; capillary permeability was measured by determining the extravascular plasma-equivalent albumin space using ¹²⁵I-albumin, ¹³¹I-albumin, and ⁵¹Cr-labeled erythrocytes.

Results  Latanoprost or PhXA34 had no or only a slight effect on the regional blood flow when measured 1, 2, 3, 4, and 6 hours after dose administration, with the exception of the anterior sclera, in which a moderate increase in blood flow was detected. No effect on capillary permeability to albumin was detected when studied 30 minutes to 2 hours and 5 to 6 hours after dose administration.

Conclusion  Latanoprost, a selective prostaglandin F receptor agonist, exerted no or only slight vascular effects for up to 6 hours after dose administration in the monkey eye, with the exception of the anterior sclera, in which a moderate increase in blood flow was detected.

Clinical Relevance  Naturally occurring prostaglandins may cause marked microcirculatory changes in the eye that could be of clinical concern. Latanoprost, a selective prostaglandin F receptor agonist, seems to be devoid of such effects.

From the Department of Neuroscience, Unit of Pharmacology, Uppsala University (Drs Stjernschantz and Resul), and the Research Laboratories of Pharmacia & Upjohn (Drs Selén and Astin and Ms Karlsson), Uppsala, Sweden. All authors were employees of Pharmacia & Upjohn at the time of the study. None of the authors have any proprietary interest in latanoprost.

RELATED ARTICLE

Latanoprost and Respiratory Function in Asthmatic Patients: Randomized, Double-Masked, Placebo-Controlled Crossover Evaluation
Jan Hedner, Bernt Everts, and Christina Ström Möller
Arch Ophthalmol. 1999;117(10):1305-1309.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma
Liu et al.
Br. J. Ophthalmol. 2002;86:1236-1239.
ABSTRACT | FULL TEXT  

Effects of Topical Latanoprost on Optic Nerve Head Circulation in Rabbits, Monkeys, and Humans
Ishii et al.
IOVS 2001;42:2957-2963.
ABSTRACT | FULL TEXT  

From PGF2{{alpha}}-Isopropyl Ester to Latanoprost: A Review of the Development of Xalatan The Proctor Lecture
Stjernschantz
IOVS 2001;42:1134-1145.
FULL TEXT  

No Relationship Between Advertising and Editorial Acceptance
Hoffman and McDonnell
Arch Ophthalmol 2001;119:308-308.
FULL TEXT